01—Abstract
Summary
Summary of the 10-Q filed May 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. reported a significant decline in revenue for the first quarter of 2024 compared to the same period in the prior year, primarily driven by a substantial decrease in net product sales of its COVID-19 vaccine.
This revenue drop reflects the market's transition to a seasonal commercial pattern for COVID-19 vaccines, with lower demand expected in the first half of the year. Despite the revenue challenges, the company continues to prioritize research and development, with a robust pipeline of 40 development candidates across various therapeutic areas. Financially, Moderna reported a net loss of $1.175 billiona for the quarter, a significant increase from the prior year's net income.
This loss was impacted by continued high R&D expenses and the shift in revenue dynamics. The company's liquidity remains strong, with a substantial amount of cash, cash equivalents, and investments, which management believes are sufficient to fund operations for at least the next 12 months. Strategic partnerships, such as the one with Blackstone for its flu program, and out-licensing agreements are being utilized to support pipeline advancement and revenue diversification.
02—Key points
Key Highlights
- Net product sales for Q1 2024 were $167 million, a 91% decrease from $1.828 billion in Q1 2023, reflecting the seasonal market shift for COVID-19 vaccines.
- The company reported a net loss of $1.175 billion for Q1 2024, compared to a net income of $79 million in Q1 2023.
- Research and Development (R&D) expenses remained substantial at $1.063 billion for Q1 2024, a 6% decrease from $1.131 billion in Q1 2023, indicating continued investment in pipeline development.
- Moderna entered into a development and commercialization funding agreement with Blackstone Life Sciences for up to $750 million to advance its flu program.
- In April 2024, the company announced a non-exclusive out-licensing agreement for COVID-19 intellectual property in Japan, receiving an upfront payment of $50 million and potential future royalties.
- The company's COVID-19 vaccine candidate, mRNA-1283, showed positive Phase 3 results, eliciting a higher immune response than the current vaccine and is refrigerator-stable, potentially for combination vaccines.
- Moderna's cash, cash equivalents, and investments totaled $12.161 billion as of March 31, 2024, providing ample liquidity for ongoing operations and future development.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 2, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $167.00M$1.86B | −91.0% |
| Cost of Revenue | $96.00M$792.00M | −87.9% |
| Gross Profit | $71.00M$1.07B | −93.4% |
| R&D Expenses | $1.06B$1.13B | −6.0% |
| Operating Expenses | $1.43B$2.23B | −35.7% |
| Operating Income | -$1.27B-$366.00M | −245.9% |
| Net Income | -$1.18B$79.00M | −1587.3% |
| EPS (Basic) | $-3.07$0.20 | −1635.0% |
| EPS (Diluted) | $-3.07$0.19 | −1715.8% |
| Shares Outstanding (Basic) | 382.00M386.00M | −1.0% |
| Shares Outstanding (Diluted) | 382.00M405.00M | −5.7% |
05—Questions
Frequently Asked Questions
What is the primary driver behind the significant decrease in revenue for Moderna in Q1 2024?
The primary driver is the substantial decline in net product sales of Moderna's COVID-19 vaccine. This decrease is attributed to the market's transition from a pandemic-driven sales environment to a seasonal commercial pattern, resulting in lower sales volumes, especially outside the United States, and a general decrease in demand during the first quarter.
How is Moderna managing its R&D investments given the current revenue environment?
Moderna continues to prioritize R&D as a key capital allocation strategy. Despite the revenue challenges, R&D expenses remain significant. The company is leveraging strategic partnerships, such as the $750 million funding agreement with Blackstone for its flu program, and out-licensing deals to support the advancement of its diverse pipeline, which includes 40 development candidates.
What is the outlook for Moderna's COVID-19 vaccine sales for the remainder of 2024?
Moderna expects the progression towards a seasonal commercial market for its COVID-19 vaccine to continue. They anticipate higher demand during the fall and winter seasons due to vaccination campaigns. However, for the full year 2024, net product sales for the COVID-19 vaccine are projected to be further reduced compared to 2023.
Does Moderna have sufficient liquidity to fund its operations and development plans?
Yes, Moderna's financial position remains strong. As of March 31, 2024, the company held $12.161 billion in cash, cash equivalents, and investments. Management believes this amount, along with expected cash generated from product sales, will be sufficient to fund projected operations and capital expenditures for at least the next 12 months.
06—Continue